About this item:

357 Views | 745 Downloads

Author Notes:

Corresponding author: John Levine, MD, MS, Blood and Marrow Transplantation Program, 1 Gustave L. Levy Pl, Box 1410, NY, NY 10029, john.levine@mssm.edu

The authors thank the many clinicians, data managers, and research staff who participated in this project.

Financial disclosure: The authors have no financial interests to disclose.


Research Funding:

This research was supported by NIH grant CA039542.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Hematology
  • Immunology
  • Transplantation
  • Bone marrow transplant
  • BMT
  • Graft-versus-host disease
  • Guidance
  • Guidelines
  • GVHD
  • staging
  • standardization

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium

Show all authors Show less authors


Journal Title:

Biology of Blood and Marrow Transplantation


Volume 22, Number 1


, Pages 4-10

Type of Work:

Article | Final Publisher PDF


Acute graft-versus-host disease (GVHD) remains a leading cause of morbidity and nonrelapse mortality after allogeneic hematopoietic cell transplantation. The clinical staging of GVHD varies greatly between transplant centers and is frequently not agreed on by independent reviewers. The lack of standardized approaches to handle common sources of discrepancy in GVHD grading likely contributes to why promising GVHD treatments reported from single centers have failed to show benefit in randomized multicenter clinical trials. We developed guidelines through international expert consensus opinion to standardize the diagnosis and clinical staging of GVHD for use in a large international GVHD research consortium. During the first year of use, the guidance followed discussion of complex clinical phenotypes by experienced transplant physicians and data managers. These guidelines increase the uniformity of GVHD symptom capture, which may improve the reproducibility of GVHD clinical trials after further prospective validation.

Copyright information:

© 2016 American Society for Blood and Marrow Transplantation.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote